IDEAS home Printed from https://ideas.repec.org/f/pma997.html
   My authors  Follow this author

Jörg C. Mahlich
(Joerg C. Mahlich)

Personal Details

First Name:Joerg
Middle Name:C.
Last Name:Mahlich
Suffix:
RePEc Short-ID:pma997
http://www.xing.com/profile/Joerg_Mahlich

Affiliation

Institut für Volkswirtschaftslehre
Fakultät für Wirtschaftswissenschaften
Universität Wien

Wien, Austria
http://econ.univie.ac.at/
RePEc:edi:wiwuwat (more details at EDIRC)

Research output

as
Jump to: Working papers Articles Chapters Books

Working papers

  1. Mahlich, Jörg & Sindern, Jörn & Suppliet, Moritz, 2014. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," DICE Ordnungspolitische Perspektiven 60, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
  2. Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," MERIT Working Papers 2006-015, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
  3. Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2001. "The Changing Nature of Pharmaceutical R&D - Opportunities for Asia?," Research Memorandum 001, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT).

Articles

  1. Martina Treskova & Stefan Scholz & Alexander Kuhlmann & Jörg Mahlich & Matthias Stoll, 2022. "Estimation of Health-State Utility Values and Factors Driving Health-Related Quality of Life in People Living with HIV and AIDS and Receiving cART in Germany: Baseline Analysis of a Cohort Study," Applied Research in Quality of Life, Springer;International Society for Quality-of-Life Studies, vol. 17(2), pages 851-869, April.
  2. Jörg Mahlich & Arne Bartol & Srirangan Dheban, 2021. "Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis," Health Economics Review, Springer, vol. 11(1), pages 1-10, December.
  3. Celine Miyazaki & Rosarin Sruamsiri & Jӧrg Mahlich & Wonjoo Jung, 2020. "Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-18, May.
  4. Timothy Bolt & Hisanori Kobayashi & Jörg Mahlich, 2019. "Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan," PharmacoEconomics - Open, Springer, vol. 3(2), pages 255-264, June.
  5. Jörg Mahlich & B. Burcin Yurtoglu, 2019. "Returns on different types of investment in the global pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 40(1), pages 16-36, January.
  6. Stephane Cheung & Yukinobu Hamuro & Jörg Mahlich & Masahiko Nakayama & Akiko Tsubota, 2018. "Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data," PLOS ONE, Public Library of Science, vol. 13(4), pages 1-15, April.
  7. Jörg Mahlich & Shinichiro Okamoto & Akiko Tsubota, 2017. "Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib," PharmacoEconomics - Open, Springer, vol. 1(3), pages 195-202, September.
  8. Philipp Hafner & Jörg C. Mahlich, 2016. "Determinants of physician's office visits and potential effects of co-payments: evidence from Austria," International Journal of Health Planning and Management, Wiley Blackwell, vol. 31(3), pages 192-203, July.
  9. Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015. "Vergleichbarkeit internationaler Arzneimittelpreise," Perspektiven der Wirtschaftspolitik, De Gruyter, vol. 16(2), pages 164-172, June.
  10. Stephan Eger & Jörg Mahlich, 2014. "Pharmaceutical regulation in Europe and its impact on corporate R&D," Health Economics Review, Springer, vol. 4(1), pages 1-9, December.
  11. Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres, 2013. "Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany," Applied Health Economics and Health Policy, Springer, vol. 11(5), pages 509-521, October.
  12. Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres, 2013. "Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany," Applied Health Economics and Health Policy, Springer, vol. 11(6), pages 689-689, December.
  13. Axel Mühlbacher & Matthias Stoll & Jörg Mahlich & Matthias Nübling, 2013. "Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment," Health Economics Review, Springer, vol. 3(1), pages 1-11, December.
  14. Hans Dimai & Kurt Redlich & Monika Peretz & Fredrik Borgström & Uwe Siebert & Jörg Mahlich, 2012. "Economic burden of osteoporotic fractures in Austria," Health Economics Review, Springer, vol. 2(1), pages 1-10, December.
  15. Jörg Mahlich, 2011. "R&D Management Of Japanese Pharmaceutical Firms," International Journal of Innovation and Technology Management (IJITM), World Scientific Publishing Co. Pte. Ltd., vol. 8(02), pages 211-226.
  16. Mahlich, Jörg C. & Yurtoglu, Burcin, 2011. "Intangibles Kapital und Rentabilität in der Pharmaindustrie," Die Unternehmung - Swiss Journal of Business Research and Practice, Nomos Verlagsgesellschaft mbH & Co. KG, vol. 65(1), pages 32-49.
  17. Jörg Mahlich, 2010. "Patents and performance in the Japanese pharmaceutical industry: An institution-based view," Asia Pacific Journal of Management, Springer, vol. 27(1), pages 99-113, March.
  18. Jörg Mahlich & Thomas Roediger-Schluga, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 28(2), pages 145-164, March.
  19. Mahlich Jörg, 2005. "Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie," Zeitschrift für Wirtschaftspolitik, De Gruyter, vol. 54(3), pages 366-390, December.

Chapters

  1. Sven Demiya-Dillenburger & Masaaki Isshiki & Jörg Mahlich, 2022. "Telemedicine in Japan: Challenges and Opportunities," Contributions to Economics, in: Stefan Walzer (ed.), Digital Healthcare in Germany, pages 85-95, Springer.
  2. Jörg Mahlich & Werner Pascha, 2007. "Introduction: Korea as a Newly Advanced Economy and the Role of Technology and Innovation," Springer Books, in: Jörg C. Mahlich & Werner Pascha (ed.), Innovation and Technology in Korea, pages 1-9, Springer.
  3. Bernhard Dachs & Jörg C. Mahlich & Georg Zahradnik, 2007. "The Technological Competencies of Korea’s Firms: A Patent Analysis," Springer Books, in: Jörg C. Mahlich & Werner Pascha (ed.), Innovation and Technology in Korea, pages 127-146, Springer.

Books

  1. Jörg Mahlich & Werner Pascha (ed.), 2012. "Korean Science and Technology in an International Perspective," Springer Books, Springer, number 978-3-7908-2753-8, September.
  2. Jörg C. Mahlich & Werner Pascha (ed.), 2007. "Innovation and Technology in Korea," Springer Books, Springer, number 978-3-7908-1914-4, September.
  3. Scharnagel, Benjamin & Mahlich, Jörg & Beck, Alex, 2006. "Das D-A-CH-Reformbarometer: Reformpolitik in Deutschland, Österreich und der Schweiz," IW-Analysen, Institut der deutschen Wirtschaft (IW) / German Economic Institute, volume 23, number 23.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Jörg Mahlich & Arne Bartol & Srirangan Dheban, 2021. "Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis," Health Economics Review, Springer, vol. 11(1), pages 1-10, December.

    Mentioned in:

    1. Chris Sampson’s journal round-up for 8th March 2021
      by Chris Sampson in The Academic Health Economists' Blog on 2021-03-08 12:00:01

Working papers

  1. Mahlich, Jörg & Sindern, Jörn & Suppliet, Moritz, 2014. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," DICE Ordnungspolitische Perspektiven 60, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).

    Cited by:

    1. Bauer, Cosima & May, Uwe, 2019. "Anpassung von AMNOG-Preisfaktoren im Zeitverlauf - Eine Analyse mit Fokus auf das Kriterium der europäischen Vergleichspreise: Gutachten für die Bristol-Myers Squibb GmbH & Co. KGaA," IBES Diskussionsbeiträge 225, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).

  2. Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," MERIT Working Papers 2006-015, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).

    Cited by:

    1. Michael C. Huang & Ming-Huan Liou & Yoko Iwaki, 2021. "The impact of R&D and innovation on global supply chain transition: GTAP analysis on Japan’s public R&D investment," Journal of Social and Economic Development, Springer;Institute for Social and Economic Change, vol. 23(3), pages 447-467, December.
    2. Ke Ding & Helian Xu & Rongming Yang, 2021. "Taxation and Enterprise Innovation: Evidence from China’s Value-Added Tax Reform," Sustainability, MDPI, vol. 13(10), pages 1-20, May.
    3. Ruchir Agarwal & Patrick Gaulé, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IMF Working Papers 2021/048, International Monetary Fund.
    4. Bryan P. Schmutz & Rexford E. Santerre, 2013. "Examining The Link Between Cash Flow, Market Value, And Research And Development Investment Spending In The Medical Device Industry," Health Economics, John Wiley & Sons, Ltd., vol. 22(2), pages 157-167, February.
    5. Bastian Rake, 2013. "Determinants of Pharmaceutical Innovation: The Role of Technological Opportunities Revisited," DRUID Working Papers 13-03, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
    6. Evens Salies, 2009. "A Test of the Schumpeterian Hypothesis in a Panel of European Electric Utilies," Post-Print hal-03416459, HAL.
    7. Desiderio Romero-Jordán & María Delgado-Rodríguez & Inmaculada Álvarez-Ayuso & Sonia Lucas-Santos, 2014. "Assessment of the public tools used to promote R&D investment in Spanish SMEs," Small Business Economics, Springer, vol. 43(4), pages 959-976, December.
    8. Civan Abdulkadir & Maloney Michael T., 2009. "The Effect of Price on Pharmaceutical R&D," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 9(1), pages 1-24, April.
    9. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
    10. Shilpi Tyagi & D. K. Nauriyal & Rachita Gulati, 2018. "Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry," Review of Managerial Science, Springer, vol. 12(1), pages 167-202, January.
    11. Jian Xu & Jae-Woo Sim, 2018. "Characteristics of Corporate R&D Investment in Emerging Markets: Evidence from Manufacturing Industry in China and South Korea," Sustainability, MDPI, vol. 10(9), pages 1-18, August.
    12. Mahlich, Jörg C. & Yurtoglu, Burcin, 2011. "Intangibles Kapital und Rentabilität in der Pharmaindustrie," Die Unternehmung - Swiss Journal of Business Research and Practice, Nomos Verlagsgesellschaft mbH & Co. KG, vol. 65(1), pages 32-49.
    13. Jörg Mahlich, 2010. "Patents and performance in the Japanese pharmaceutical industry: An institution-based view," Asia Pacific Journal of Management, Springer, vol. 27(1), pages 99-113, March.
    14. Sophie Nivoix & Pascal Nguyen, 2012. "Characteristics of R&D expenditures in Japan's pharmaceutical industry," Asia Pacific Business Review, Taylor & Francis Journals, vol. 18(2), pages 225-240, April.
    15. Stephan Eger & Jörg Mahlich, 2014. "Pharmaceutical regulation in Europe and its impact on corporate R&D," Health Economics Review, Springer, vol. 4(1), pages 1-9, December.

  3. Mahlich, Jörg C. & Roediger-Schluga, Thomas, 2001. "The Changing Nature of Pharmaceutical R&D - Opportunities for Asia?," Research Memorandum 001, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT).

    Cited by:

    1. Patrick Cohendet & Matthieu Farcot & Julien Pénin, 2009. "Intellectual property in a knowledge-based economy : Patents to include vs. patents to exclude," Working Papers of BETA 2009-15, Bureau d'Economie Théorique et Appliquée, UDS, Strasbourg.

Articles

  1. Jörg Mahlich & B. Burcin Yurtoglu, 2019. "Returns on different types of investment in the global pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 40(1), pages 16-36, January.

    Cited by:

    1. Jörg Mahlich & Arne Bartol & Srirangan Dheban, 2021. "Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis," Health Economics Review, Springer, vol. 11(1), pages 1-10, December.
    2. Julen Castillo‐Apraiz & Jesus Matey, 2020. "Customizing competitive strategy to entry timing: Implications for firm performance in the pharmaceutical industry," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 41(6), pages 976-985, September.

  2. Philipp Hafner & Jörg C. Mahlich, 2016. "Determinants of physician's office visits and potential effects of co-payments: evidence from Austria," International Journal of Health Planning and Management, Wiley Blackwell, vol. 31(3), pages 192-203, July.

    Cited by:

    1. O’Brien, Gary L. & Sinnott, Sarah-Jo & O’ Flynn, Bridget & Walshe, Valerie & Mulcahy, Mark & Byrne, Stephen, 2020. "Out of pocket or out of control: A qualitative analysis of healthcare professional stakeholder involvement in pharmaceutical policy change in Ireland," Health Policy, Elsevier, vol. 124(4), pages 411-418.
    2. Timothy Bolt & Hisanori Kobayashi & Jörg Mahlich, 2019. "Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan," PharmacoEconomics - Open, Springer, vol. 3(2), pages 255-264, June.

  3. Mahlich Jörg & Sindern Jörn & Suppliet Moritz, 2015. "Vergleichbarkeit internationaler Arzneimittelpreise," Perspektiven der Wirtschaftspolitik, De Gruyter, vol. 16(2), pages 164-172, June.
    See citations under working paper version above.
  4. Stephan Eger & Jörg Mahlich, 2014. "Pharmaceutical regulation in Europe and its impact on corporate R&D," Health Economics Review, Springer, vol. 4(1), pages 1-9, December.

    Cited by:

    1. Moreno Gigi & van Eijndhoven Emma & Benner Jennifer & Sullivan Jeffrey, 2017. "The Long-Term Impact of Price Controls in Medicare Part D," Forum for Health Economics & Policy, De Gruyter, vol. 20(2), pages 1-56, December.
    2. Stojchevska, Ivana & Baftijari, Agon, 2015. "The Impact of Governmental Policy on R&D Projects in the Pharmaceutical Industry," Proceedings of the ENTRENOVA - ENTerprise REsearch InNOVAtion Conference (2015), Kotor, Montengero, in: Proceedings of the ENTRENOVA - ENTerprise REsearch InNOVAtion Conference, Kotor, Montengero, 10-11 September 2015, pages 72-79, IRENET - Society for Advancing Innovation and Research in Economy, Zagreb.
    3. Mujaheed Shaikh & Pietro del Giudice & Dimitrios Kourouklis, 2020. "Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment," Post-Print hal-03046856, HAL.
    4. Jörg Mahlich & Arne Bartol & Srirangan Dheban, 2021. "Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis," Health Economics Review, Springer, vol. 11(1), pages 1-10, December.

  5. Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres, 2013. "Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany," Applied Health Economics and Health Policy, Springer, vol. 11(5), pages 509-521, October.

    Cited by:

    1. Sylvain Druais & Agathe Doutriaux & Magali Cognet & Annabelle Godet & Christophe Lançon & Pierre Levy & Ludovic Samalin & Pascal Guillon, 2016. "Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France," PharmacoEconomics, Springer, vol. 34(4), pages 363-391, April.
    2. Huajie Jin & Paul Tappenden & Stewart Robinson & Evanthia Achilla & James H. MacCabe & David Aceituno & Sarah Byford, 2020. "A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway," PharmacoEconomics, Springer, vol. 38(6), pages 537-555, June.

  6. Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres, 2013. "Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany," Applied Health Economics and Health Policy, Springer, vol. 11(6), pages 689-689, December.

    Cited by:

    1. Sylvain Druais & Agathe Doutriaux & Magali Cognet & Annabelle Godet & Christophe Lançon & Pierre Levy & Ludovic Samalin & Pascal Guillon, 2016. "Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France," PharmacoEconomics, Springer, vol. 34(4), pages 363-391, April.
    2. Huajie Jin & Paul Tappenden & Stewart Robinson & Evanthia Achilla & James H. MacCabe & David Aceituno & Sarah Byford, 2020. "A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway," PharmacoEconomics, Springer, vol. 38(6), pages 537-555, June.

  7. Axel Mühlbacher & Matthias Stoll & Jörg Mahlich & Matthias Nübling, 2013. "Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment," Health Economics Review, Springer, vol. 3(1), pages 1-11, December.

    Cited by:

    1. Timothy Bolt & Hisanori Kobayashi & Jörg Mahlich, 2019. "Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan," PharmacoEconomics - Open, Springer, vol. 3(2), pages 255-264, June.

  8. Hans Dimai & Kurt Redlich & Monika Peretz & Fredrik Borgström & Uwe Siebert & Jörg Mahlich, 2012. "Economic burden of osteoporotic fractures in Austria," Health Economics Review, Springer, vol. 2(1), pages 1-10, December.

    Cited by:

    1. Hans Concin & Wolfgang Brozek & Karl-Peter Benedetto & Hartmut Häfele & Joachim Kopf & Thomas Bärenzung & Richard Schnetzer & Christian Schenk & Elmar Stimpfl & Ursula Waheed-Hutter & Hanno Ulmer & Ki, 2016. "Hip fracture incidence 2003–2013 and projected cases until 2050 in Austria: a population-based study," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 61(9), pages 1021-1030, December.

  9. Mahlich, Jörg C. & Yurtoglu, Burcin, 2011. "Intangibles Kapital und Rentabilität in der Pharmaindustrie," Die Unternehmung - Swiss Journal of Business Research and Practice, Nomos Verlagsgesellschaft mbH & Co. KG, vol. 65(1), pages 32-49.

    Cited by:

    1. Tami Dinh Thi & Wolfgang Schultze, 2011. "Capitalizing research & development and ‘other information’: the incremental information content of accruals versus cash flows," Metrika: International Journal for Theoretical and Applied Statistics, Springer, vol. 22(3), pages 241-278, November.

  10. Jörg Mahlich, 2010. "Patents and performance in the Japanese pharmaceutical industry: An institution-based view," Asia Pacific Journal of Management, Springer, vol. 27(1), pages 99-113, March.

    Cited by:

    1. Megan Min Zhang & Paul W. Beamish, 2019. "An institutional response model to economic liberalization: Japanese MNEs’ ownership choices in China," Asia Pacific Journal of Management, Springer, vol. 36(1), pages 33-59, March.
    2. Patricia Laurens & Christian Le Bas & Antoine Schoen, 2019. "Worldwide IP coverage of patented inventions in large pharma firms: to what extent do the internationalisation of R&D and firm strategy matter?," Post-Print hal-01725229, HAL.
    3. Lechevalier, Sébastien & Nishimura, Junichi & Storz, Cornelia, 2014. "Diversity in patterns of industry evolution: How an intrapreneurial regime contributed to the emergence of the service robot industry," Research Policy, Elsevier, vol. 43(10), pages 1716-1729.
    4. Inês Teixeira & Aurora Teixeira & Luís Santos, 2023. "R&D subsidies and Portuguese firms’ performance: A longitudinal firm-level study," GEE Papers 0173, Gabinete de Estratégia e Estudos, Ministério da Economia, revised Jul 2023.
    5. Yagi, Michiyuki & Managi, Shunsuke, 2018. "Shadow price of patent stock as knowledge stock: Time and country heterogeneity," MPRA Paper 89146, University Library of Munich, Germany.
    6. Ovsiannikov, Kostiantyn, 2020. "Does Tokyo Stock Exchange Appreciate Corporate Innovations? Role of Patents’ Quality and Research Productivity," SocArXiv k4ys6, Center for Open Science.
    7. Xiaoqing Li & Yu Zheng & Catherine L. Wang, 2016. "Inter-firm collaboration in new product development in Chinese pharmaceutical companies," Asia Pacific Journal of Management, Springer, vol. 33(1), pages 165-193, March.
    8. Wei‐Kang Wang & Wen‐Min Lu & Qian Long Kweh & Hoang Tu Nhi Truong, 2020. "What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 41(5), pages 762-770, July.

  11. Jörg Mahlich & Thomas Roediger-Schluga, 2006. "The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 28(2), pages 145-164, March.
    See citations under working paper version above.
  12. Mahlich Jörg, 2005. "Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie," Zeitschrift für Wirtschaftspolitik, De Gruyter, vol. 54(3), pages 366-390, December.

    Cited by:

    1. Mahlich, Jörg C. & Yurtoglu, Burcin, 2011. "Intangibles Kapital und Rentabilität in der Pharmaindustrie," Die Unternehmung - Swiss Journal of Business Research and Practice, Nomos Verlagsgesellschaft mbH & Co. KG, vol. 65(1), pages 32-49.

Chapters

  1. Jörg Mahlich & Werner Pascha, 2007. "Introduction: Korea as a Newly Advanced Economy and the Role of Technology and Innovation," Springer Books, in: Jörg C. Mahlich & Werner Pascha (ed.), Innovation and Technology in Korea, pages 1-9, Springer.

    Cited by:

    1. Park, Han Woo & Leydesdorff, Loet, 2010. "Longitudinal trends in networks of university-industry-government relations in South Korea: The role of programmatic incentives," Research Policy, Elsevier, vol. 39(5), pages 640-649, June.
    2. Cardinale, Roberto, 2019. "Theory and practice of State intervention: Italy, South Korea and stages of economic development," Structural Change and Economic Dynamics, Elsevier, vol. 49(C), pages 206-216.

Books

  1. Jörg Mahlich & Werner Pascha (ed.), 2012. "Korean Science and Technology in an International Perspective," Springer Books, Springer, number 978-3-7908-2753-8, September.

    Cited by:

    1. Jan Melissen & Emillie V. Keulenaar, 2017. "Critical Digital Diplomacy as a Global Challenge: The South Korean Experience," Global Policy, London School of Economics and Political Science, vol. 8(3), pages 294-302, September.
    2. Schüler, Diana & Suhalitca, Mihaela & Pascha, Werner & Oh, Keun-yeob, 2020. "Government policies for start-ups in Korea and its regions: Motives, mechanisms and major obstacles," Working Papers on East Asian Studies 127/2020, University of Duisburg-Essen, Institute of East Asian Studies IN-EAST.
    3. Jitendra Uttam, 2019. "Beyond Neo-liberalism: Analyzing the ‘Post-Developmental State’ in South Korea," International Studies, , vol. 56(4), pages 236-254, October.
    4. Larson, James F. & Park, Jaemin, 2014. "From developmental to network state: Government restructuring and ICT-led innovation in Korea," Telecommunications Policy, Elsevier, vol. 38(4), pages 344-359.

  2. Jörg C. Mahlich & Werner Pascha (ed.), 2007. "Innovation and Technology in Korea," Springer Books, Springer, number 978-3-7908-1914-4, September.

    Cited by:

    1. Lee, Keun & Malerba, Franco, 2017. "Catch-up cycles and changes in industrial leadership:Windows of opportunity and responses of firms and countries in the evolution of sectoral systems," Research Policy, Elsevier, vol. 46(2), pages 338-351.
    2. Edwin Garces & Tugrul Daim, 2012. "Impact of Renewable Energy Technology on the Economic Growth of the USA," Journal of the Knowledge Economy, Springer;Portland International Center for Management of Engineering and Technology (PICMET), vol. 3(3), pages 233-249, September.
    3. Park, Han Woo & Leydesdorff, Loet, 2010. "Longitudinal trends in networks of university-industry-government relations in South Korea: The role of programmatic incentives," Research Policy, Elsevier, vol. 39(5), pages 640-649, June.
    4. Pieter Stek & Marina Geenhuizen, 2015. "Measuring the dynamics of an innovation system using patent data: a case study of South Korea, 2001–2010," Quality & Quantity: International Journal of Methodology, Springer, vol. 49(4), pages 1325-1343, July.
    5. Wong, Chan-Yuan & Goh, Kim-Leng, 2012. "The sustainability of functionality development of science and technology: Papers and patents of emerging economies," Journal of Informetrics, Elsevier, vol. 6(1), pages 55-65.
    6. Cardinale, Roberto, 2019. "Theory and practice of State intervention: Italy, South Korea and stages of economic development," Structural Change and Economic Dynamics, Elsevier, vol. 49(C), pages 206-216.
    7. Werner Pascha & Cornelia Storz & Markus Taube, 2011. "Coordination between Inertia and Dynamic Development: An Overview of Issues and Contributions," Chapters, in: Werner Pascha & Cornelia Storz & Markus Taube (ed.), Institutional Variety in East Asia, chapter 1, Edward Elgar Publishing.
    8. Mohammed Ahmad S. Al-Shamsi, 2022. "Review of Korean Imitation and Innovation in the Last 60 Years," Sustainability, MDPI, vol. 14(6), pages 1-15, March.
    9. Martin Hemmert, 2019. "The relevance of inter-personal ties and inter-organizational tie strength for outcomes of research collaborations in South Korea," Asia Pacific Journal of Management, Springer, vol. 36(2), pages 373-393, June.
    10. Ekaterina Streltsova & Gleb Kuzmin, 2019. "Russian Technograds: The Technological Profiles of the Cities," Foresight and STI Governance (Foresight-Russia till No. 3/2015), National Research University Higher School of Economics, vol. 13(3), pages 41-49.
    11. Dominik F. Schlossstein, 2011. "Institutions and Organizations in Korea’s Upstream Innovation Governance: A Search for Adaptive Efficiency?," Chapters, in: Werner Pascha & Cornelia Storz & Markus Taube (ed.), Institutional Variety in East Asia, chapter 6, Edward Elgar Publishing.
    12. Hemmert, Martin, 2015. "The relevance of inter-personal and inter-organizational ties for interaction quality and outcomes of research collaborations in South Korea," Working Papers on East Asian Studies 102/2015, University of Duisburg-Essen, Institute of East Asian Studies IN-EAST.
    13. Park, Jong-Hyun & Kim, Yun Bae & Kim, Moon-Koo, 2017. "Investigating factors influencing the market success or failure of IT services in Korea," International Journal of Information Management, Elsevier, vol. 37(1), pages 1418-1427.
    14. Wong, Chan-Yuan & Goh, Kim-Leng, 2010. "Growth behavior of publications and patents: A comparative study on selected Asian economies," Journal of Informetrics, Elsevier, vol. 4(4), pages 460-474.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 2 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-GER: German Papers (1) 2014-05-24
  2. NEP-HEA: Health Economics (1) 2006-05-27
  3. NEP-INO: Innovation (1) 2006-05-27
  4. NEP-SEA: South East Asia (1) 2006-05-27
  5. NEP-TID: Technology and Industrial Dynamics (1) 2006-05-27

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Joerg C. Mahlich
(Joerg C. Mahlich) should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.